Opinion

Video

Clinical Insights on Managing Ruxolitinib Cytopenias: Patient-Focused Approach

Author(s):

Andrew Kuykendall, MD,Venu Konala, MD

Panelists discuss the patient and disease characteristics influencing the decision to dose-reduce ruxolitinib vs switching therapy. They share their typical sequencing approach after first-line ruxolitinib, including whether a washout period or overlap is required.

  1. Dr Kuykendall to Dr Konala: What patient and/or disease characteristics do you consider when deciding to dose-reduce ruxolitinib vs change therapy? How do you take into account your patient’s preference in this situation?
  2. Dr Kuykendall: Please share your typical sequencing approach post first-line ruxolitinib. What does the process look like? Does it require a washout period or overlap?
Related Videos
Related Content